{
    "name": "axicabtagene ciloleucel",
    "comment": "Rx",
    "other_names": [
        "Yescarta"
    ],
    "classes": [
        "CAR-T Cell Therapies"
    ],
    "source": "https://reference.medscape.com/drug/yescarta-axicabtagene-ciloleucel-1000187",
    "pregnancy": {
        "common": [
            "Data are not available in pregnant women",
            "No animal reproductive and developmental toxicity studies have been conducted",
            "Based on the mechanism of action, if the transduced cells cross the placenta, they may cause fetal toxicity, including B-cell lymphocytopenia",
            "Therefore, axicabtagene ciloleucel is not recommended for women who are pregnant, and pregnancy after infusion should be discussed with the treating physician",
            "Pregnancy status of females with reproductive potential should be verified; sexually active females of reproductive potential should have a pregnancy test prior to starting treatment",
            "Contraception: See the prescribing information for fludarabine and cyclophosphamide for information on the need for effective contraception in patients who receive the lymphodepleting chemotherapy; limited exposure data available concerning the duration of contraception following treatment with axicabtagene ciloleucel"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Cytokine release syndrome",
                    "description": [
                        "Cytokine release syndrome (CRS), including fatal or life-threatening reactions, reported in a majority of patients (see Adverse Effects)",
                        "Median time to CRS onset was 2 days (range: 1-12 days)",
                        "Median duration of CRS was 7 days (range: 2-58 days)",
                        "Key manifestations of CRS include high fever, hypotension, tachycardia, hypoxia, and chills",
                        "Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)",
                        "Do not administer to patients with active infection or inflammatory disorders",
                        "Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids ",
                        "Ensure that 2 doses of tocilizumab are available on site prior to initiating axicabtagene ciloleucel (see Dosage Modifications)",
                        "Monitor for CRS signs or symptoms daily for at least 7 days at the certified healthcare facility following treatment; continue monitoring for 4 weeks following the infusion",
                        "Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time",
                        "At the first sign of CRS, immediately evaluate patient for hospitalization and institute treatment with supportive care, tocilizumab, and/or corticosteroids as indicated"
                    ]
                },
                {
                    "type": "Neurological toxicities",
                    "description": [
                        "Ensure that 2 doses of tocilizumab are available on site prior to initiating axicabtagene ciloleucel (see Dosage Modifications)",
                        "Monitor for CRS signs or symptoms daily for at least 7 days at the certified healthcare facility following treatment; continue monitoring for 4 weeks following the infusion",
                        "Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time",
                        "At the first sign of CRS, immediately evaluate patient for hospitalization and institute treatment with supportive care, tocilizumab, and/or corticosteroids as indicated"
                    ]
                },
                {
                    "type": "Restricted access program",
                    "description": [
                        "Neurological toxicities, which may be severe or life-threatening, can occur following treatment, including concurrently with CRS",
                        "The majority of neurological toxicities occurred within 8 weeks after treatment",
                        "The most common neurological toxicities were encephalopathy, headache, tremor, dizziness, aphasia, delirium, insomnia, and anxiety (also see Adverse Effects)",
                        "Prolonged encephalopathy lasting up to 173 days was observed",
                        "Serious events, including leukoencephalopathy and seizures, occurred in clinical trials",
                        "Fatal and serious cases of cerebral edema also occurred",
                        "Monitor for neurological events after treatment; provide supportive care as needed"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred following treatment in most patients (see Black Box Warnings)",
                "Neurological toxicities, which may be severe or life-threatening, can occur following treatment (see Black Box Warnings)",
                "Prophylactic corticosteroids for CRS and neurologic toxicities may result in higher grade of neurologic toxicities or prolongation of neurologic toxicities, delay onset and decrease duration of CRS; consider the risk and benefits of prophylactic corticosteroids in patients with pre-existing comorbidities and the potential for the risk of Grade 4 and prolonged neurologic toxicities",
                "Available only through a restricted access program (see Black Box Warnings)",
                "Allergic reactions may occur during infusion; serious hypersensitivity reactions, including anaphylaxis, may be due to the dimethyl sulfoxide (DMSO) or residual gentamicin in the product",
                "Serious infections, including life-threatening or fatal infections, reported; before administering, infection prophylaxis for neutropenia should follow local guidelines; monitor for signs and symptoms of infection after treatment and treat appropriately",
                "Viral reactivation can occur; hepatitis B virus (HBV) reactivation can result in fulminant hepatitis, hepatic failure, and death; perform screening for HBV, hepatitis C virus (HCV), and HIV in accordance with clinical guidelines before collection of cells for manufacturing",
                "Prolonged cytopenias may occur and last for several weeks following lymphodepleting chemotherapy and axicabtagene ciloleucel infusion; monitor blood cell counts",
                "B-cell aplasia and hypogammaglobulinemia can occur; monitor immunoglobulin levels after treatment and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement standard guidelines",
                "Secondary malignancies may develop; monitor patient life-long for secondary malignancies",
                "Owing to the potential for neurological events, including altered mental status or seizures, patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following treatment; advise patients to refrain from driving and engaging in hazardous occupations or activities"
            ],
            "specific": [
                {
                    "type": "Immunization with live viral vaccines",
                    "description": [
                        "The safety of immunization with live viral vaccines during or following treatment has not been studied",
                        "Vaccination with live-virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during axicabtagene ciloleucel treatment, and until immune recovery afterwards"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abatacept",
            "description": {
                "common": "abatacept, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abrocitinib",
            "description": {
                "common": "abrocitinib, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adalimumab",
            "description": {
                "common": "adalimumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during axicabtagene ciloleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ado-trastuzumab emtansine",
            "description": {
                "common": "ado-trastuzumab emtansine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alefacept",
            "description": {
                "common": "alefacept, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alemtuzumab",
            "description": {
                "common": "alemtuzumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anakinra",
            "description": {
                "common": "anakinra, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ansuvimab",
            "description": {
                "common": "ansuvimab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin equine",
            "description": {
                "common": "antithymocyte globulin equine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin rabbit",
            "description": {
                "common": "antithymocyte globulin rabbit, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apaziquone",
            "description": {
                "common": "apaziquone, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atoltivimab/maftivimab/odesivimab",
            "description": {
                "common": "atoltivimab/maftivimab/odesivimab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azathioprine",
            "description": {
                "common": "azathioprine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "balstilimab",
            "description": {
                "common": "balstilimab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baricitinib",
            "description": {
                "common": "baricitinib, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "basiliximab",
            "description": {
                "common": "basiliximab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bendamustine",
            "description": {
                "common": "bendamustine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benralizumab",
            "description": {
                "common": "benralizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benznidazole",
            "description": {
                "common": "benznidazole, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "betamethasone",
            "description": {
                "common": "betamethasone, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bevacizumab",
            "description": {
                "common": "bevacizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bezlotoxumab",
            "description": {
                "common": "bezlotoxumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bimekizumab",
            "description": {
                "common": "bimekizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "botulism immune globulin iv",
            "description": {
                "common": "botulism immune globulin iv, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brodalumab",
            "description": {
                "common": "brodalumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "busulfan",
            "description": {
                "common": "busulfan, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "C1 esterase inhibitor recombinant",
            "description": {
                "common": "C1 esterase inhibitor recombinant, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "C1 inhibitor human",
            "description": {
                "common": "C1 inhibitor human, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "canakinumab",
            "description": {
                "common": "canakinumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "capecitabine",
            "description": {
                "common": "capecitabine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "caplacizumab",
            "description": {
                "common": "caplacizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carboplatin",
            "description": {
                "common": "carboplatin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carmustine",
            "description": {
                "common": "carmustine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "certolizumab pegol, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cetuximab",
            "description": {
                "common": "cetuximab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "chlorambucil, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisplatin",
            "description": {
                "common": "cisplatin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cladribine",
            "description": {
                "common": "cladribine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clofarabine",
            "description": {
                "common": "clofarabine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "corticotropin",
            "description": {
                "common": "corticotropin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cytarabine",
            "description": {
                "common": "cytarabine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cytomegalovirus immune globulin (CMV IG)",
            "description": {
                "common": "cytomegalovirus immune globulin (CMV IG), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "dacarbazine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "daclizumab",
            "description": {
                "common": "daclizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "daratumumab",
            "description": {
                "common": "daratumumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "denosumab",
            "description": {
                "common": "denosumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dimethyl fumarate",
            "description": {
                "common": "dimethyl fumarate, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dinutuximab",
            "description": {
                "common": "dinutuximab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diroximel fumarate",
            "description": {
                "common": "diroximel fumarate, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dupilumab",
            "description": {
                "common": "dupilumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Ebola Zaire vaccine",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live virus vaccines is not recommended for at least 6 weeks before starting lymphodepleting chemotherapy, during CAR-T cell treatment, and until immune recovery following treatment. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ecallantide",
            "description": {
                "common": "ecallantide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eculizumab",
            "description": {
                "common": "eculizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elotuzumab",
            "description": {
                "common": "elotuzumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "emapalumab",
            "description": {
                "common": "emapalumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "emicizumab",
            "description": {
                "common": "emicizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etanercept",
            "description": {
                "common": "etanercept, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "filgotinib",
            "description": {
                "common": "filgotinib, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fingolimod",
            "description": {
                "common": "fingolimod, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "floxuridine",
            "description": {
                "common": "floxuridine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fludarabine",
            "description": {
                "common": "fludarabine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluorouracil",
            "description": {
                "common": "fluorouracil, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gemcitabine",
            "description": {
                "common": "gemcitabine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gemtuzumab",
            "description": {
                "common": "gemtuzumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glatiramer",
            "description": {
                "common": "glatiramer, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "golimumab",
            "description": {
                "common": "golimumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "guselkumab",
            "description": {
                "common": "guselkumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hepatitis B immune globulin (HBIG)",
            "description": {
                "common": "hepatitis B immune globulin (HBIG), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "hydroxychloroquine sulfate, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "hydroxyurea, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibritumomab tiuxetan",
            "description": {
                "common": "ibritumomab tiuxetan, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "icatibant",
            "description": {
                "common": "icatibant, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "immune globulin IM (IGIM)",
            "description": {
                "common": "immune globulin IM (IGIM), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "immune globulin IV (IGIV)",
            "description": {
                "common": "immune globulin IV (IGIV), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "immune globulin SC",
            "description": {
                "common": "immune globulin SC, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "inebilizumab",
            "description": {
                "common": "inebilizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "infliximab",
            "description": {
                "common": "infliximab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon alfa n3",
            "description": {
                "common": "interferon alfa n3, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon alfacon 1",
            "description": {
                "common": "interferon alfacon 1, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon beta 1a",
            "description": {
                "common": "interferon beta 1a, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon beta 1b",
            "description": {
                "common": "interferon beta 1b, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iodoquinol",
            "description": {
                "common": "iodoquinol, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ipilimumab",
            "description": {
                "common": "ipilimumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ixekizumab",
            "description": {
                "common": "ixekizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leflunomide",
            "description": {
                "common": "leflunomide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lurbinectedin",
            "description": {
                "common": "lurbinectedin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during axicabtagene ciloleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during axicabtagene ciloleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mechlorethamine topical",
            "description": {
                "common": "mechlorethamine topical, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "melphalan",
            "description": {
                "common": "melphalan, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "melphalan flufenamide",
            "description": {
                "common": "melphalan flufenamide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mepolizumab",
            "description": {
                "common": "mepolizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "mercaptopurine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methotrexate",
            "description": {
                "common": "methotrexate, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mineral oil topical",
            "description": {
                "common": "mineral oil topical, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mitoxantrone",
            "description": {
                "common": "mitoxantrone, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mogamulizumab",
            "description": {
                "common": "mogamulizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mometasone sinus implant",
            "description": {
                "common": "mometasone sinus implant, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "monomethyl fumarate",
            "description": {
                "common": "monomethyl fumarate, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "moxetumomab pasudotox",
            "description": {
                "common": "moxetumomab pasudotox, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "muromonab CD3",
            "description": {
                "common": "muromonab CD3, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "mycophenolate, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "narsoplimab",
            "description": {
                "common": "narsoplimab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "natalizumab",
            "description": {
                "common": "natalizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelarabine",
            "description": {
                "common": "nelarabine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitazoxanide",
            "description": {
                "common": "nitazoxanide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nivolumab",
            "description": {
                "common": "nivolumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "obinutuzumab",
            "description": {
                "common": "obinutuzumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ocrelizumab",
            "description": {
                "common": "ocrelizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofatumumab",
            "description": {
                "common": "ofatumumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olaratumab",
            "description": {
                "common": "olaratumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omalizumab",
            "description": {
                "common": "omalizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oportuzumab monatox",
            "description": {
                "common": "oportuzumab monatox, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of axicabtagene ciloleucel by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "panitumumab",
            "description": {
                "common": "panitumumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paromomycin",
            "description": {
                "common": "paromomycin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "peginterferon beta-1a",
            "description": {
                "common": "peginterferon beta-1a, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pembrolizumab",
            "description": {
                "common": "pembrolizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pemetrexed",
            "description": {
                "common": "pemetrexed, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentostatin",
            "description": {
                "common": "pentostatin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimecrolimus",
            "description": {
                "common": "pimecrolimus, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pralatrexate",
            "description": {
                "common": "pralatrexate, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rabies immune globulin, human (RIG)",
            "description": {
                "common": "rabies immune globulin, human (RIG), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ravulizumab",
            "description": {
                "common": "ravulizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "raxibacumab",
            "description": {
                "common": "raxibacumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "reltecimod",
            "description": {
                "common": "reltecimod, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "remestemcel-L",
            "description": {
                "common": "remestemcel-L, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "reslizumab",
            "description": {
                "common": "reslizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Rho(D) immune globulin",
            "description": {
                "common": "Rho(D) immune globulin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rilonacept",
            "description": {
                "common": "rilonacept, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "risankizumab",
            "description": {
                "common": "risankizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab",
            "description": {
                "common": "rituximab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab-hyaluronidase",
            "description": {
                "common": "rituximab-hyaluronidase, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of rotavirus oral vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during axicabtagene ciloleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "ruxolitinib topical, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sarilumab",
            "description": {
                "common": "sarilumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secukinumab",
            "description": {
                "common": "secukinumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siltuximab",
            "description": {
                "common": "siltuximab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sintilimab",
            "description": {
                "common": "sintilimab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus",
            "description": {
                "common": "sirolimus, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus intravitreal",
            "description": {
                "common": "sirolimus intravitreal, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirukumab",
            "description": {
                "common": "sirukumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during axicabtagene ciloleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "spesolimab",
            "description": {
                "common": "spesolimab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "streptozocin",
            "description": {
                "common": "streptozocin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "sulfasalazine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sutimlimab",
            "description": {
                "common": "sutimlimab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus ointment",
            "description": {
                "common": "tacrolimus ointment, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "temozolomide",
            "description": {
                "common": "temozolomide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teplizumab",
            "description": {
                "common": "teplizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teriflunomide",
            "description": {
                "common": "teriflunomide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetanus immune globulin (TIG)",
            "description": {
                "common": "tetanus immune globulin (TIG), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thioguanine",
            "description": {
                "common": "thioguanine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thiotepa",
            "description": {
                "common": "thiotepa, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tinidazole",
            "description": {
                "common": "tinidazole, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "tocilizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "tofacitinib, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tositumomab",
            "description": {
                "common": "tositumomab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trabectedin",
            "description": {
                "common": "trabectedin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tralokinumab",
            "description": {
                "common": "tralokinumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "treosulfan",
            "description": {
                "common": "treosulfan, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triamcinolone acetonide extended-release injectable suspension",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "upadacitinib, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "ustekinumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vaccinia immune globulin intravenous",
            "description": {
                "common": "vaccinia immune globulin intravenous, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of varicella virus vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during axicabtagene ciloleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella zoster immune globulin, human",
            "description": {
                "common": "varicella zoster immune globulin, human, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vedolizumab",
            "description": {
                "common": "vedolizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of yellow fever vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during axicabtagene ciloleucel treatment, and after treatment until full immune recovery is achieved."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "axicabtagene ciloleucel decreases effects of zoster vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid live virus vaccines for at least 6 weeks before initiating lymphodepleting therapy, during axicabtagene ciloleucel treatment, and after treatment until full immune recovery is achieved."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Cytokine release syndrome",
            "percent": "94"
        },
        {
            "name": "Fever",
            "percent": "86"
        },
        {
            "name": "Tachycardia",
            "percent": "57"
        },
        {
            "name": "Encephalopathy",
            "percent": "57"
        },
        {
            "name": "Hypotension",
            "percent": "57"
        },
        {
            "name": "Fatigue",
            "percent": "46"
        },
        {
            "name": "Headache",
            "percent": "45"
        },
        {
            "name": "Decreased appetite",
            "percent": "44"
        },
        {
            "name": "Chills",
            "percent": "40"
        },
        {
            "name": "Diarrhea",
            "percent": "38"
        },
        {
            "name": "Nausea",
            "percent": "34"
        },
        {
            "name": "Hypoxia",
            "percent": "32"
        },
        {
            "name": "Tremor",
            "percent": "31"
        },
        {
            "name": "Cough",
            "percent": "30"
        },
        {
            "name": "Vomiting",
            "percent": "26"
        },
        {
            "name": "Infections",
            "percent": "26"
        },
        {
            "name": "pathogen unspecified",
            "percent": "23"
        },
        {
            "name": "Constipation",
            "percent": "23"
        },
        {
            "name": "Arrhythmia",
            "percent": "21"
        },
        {
            "name": "Dizziness",
            "percent": "19"
        },
        {
            "name": "Edema",
            "percent": "19"
        },
        {
            "name": "Motor dysfunction",
            "percent": "19"
        },
        {
            "name": "Dyspnea",
            "percent": "18"
        },
        {
            "name": "Aphasia",
            "percent": "17"
        },
        {
            "name": "Pain in extremity",
            "percent": "17"
        },
        {
            "name": "Delirium",
            "percent": "16"
        },
        {
            "name": "Weight decreased",
            "percent": "15"
        },
        {
            "name": "Hypogammaglobulinemia",
            "percent": "15"
        },
        {
            "name": "Back pain",
            "percent": "15"
        },
        {
            "name": "Hypertension",
            "percent": "14"
        },
        {
            "name": "Abdominal pain",
            "percent": "14"
        },
        {
            "name": "Muscle pain",
            "percent": "13"
        },
        {
            "name": "Pleural effusion",
            "percent": "12"
        },
        {
            "name": "Renal insufficiency",
            "percent": "11"
        },
        {
            "name": "Dry mouth",
            "percent": "11"
        },
        {
            "name": "Dehydration",
            "percent": "100"
        },
        {
            "name": "Lymphopenia",
            "percent": "96"
        },
        {
            "name": "Leukopenia",
            "percent": "93"
        },
        {
            "name": "Neutropenia",
            "percent": "66"
        },
        {
            "name": "Anemia",
            "percent": "58"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "50"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "29"
        },
        {
            "name": "Encephalopathy",
            "percent": "19"
        },
        {
            "name": "Hyponatremia",
            "percent": "16"
        },
        {
            "name": "Fever",
            "percent": "16"
        },
        {
            "name": "Infections",
            "percent": "15"
        },
        {
            "name": "pathogen unspecified",
            "percent": "13"
        },
        {
            "name": "Hypotension",
            "percent": "13"
        },
        {
            "name": "Cytokine release syndrome",
            "percent": "13"
        },
        {
            "name": "Hyperuricemia",
            "percent": "11"
        },
        {
            "name": "Direct bilirubin increased",
            "percent": "10"
        },
        {
            "name": "Hypoxia",
            "percent": "10"
        },
        {
            "name": "Arthralgia",
            "percent": "9"
        },
        {
            "name": "Thrombosis",
            "percent": "9"
        },
        {
            "name": "Pulmonary edema",
            "percent": "6"
        },
        {
            "name": "Rash",
            "percent": "6"
        },
        {
            "name": "Cardiac failure",
            "percent": "5"
        },
        {
            "name": "Ataxia",
            "percent": "4"
        },
        {
            "name": "Fungal infections",
            "percent": "4"
        },
        {
            "name": "Cardiac arrest",
            "percent": "3"
        },
        {
            "name": "Seizure",
            "percent": "2"
        },
        {
            "name": "Capillary leak syndrome",
            "percent": "2"
        },
        {
            "name": "Coagulopathy",
            "percent": "2"
        },
        {
            "name": "Dyscalculia",
            "percent": "1"
        },
        {
            "name": "Myoclonus",
            "percent": "1"
        },
        {
            "name": "Hemophagocytic lymphohistiocytosis",
            "percent": "10"
        },
        {
            "name": "macrophage activation syndrome",
            "percent": "10"
        },
        {
            "name": "HLH",
            "percent": "9"
        },
        {
            "name": "MAS",
            "percent": "7"
        },
        {
            "name": "Hypersensitivity",
            "percent": "6"
        },
        {
            "name": "Hypokalemia",
            "percent": "6"
        },
        {
            "name": "Increased ALT",
            "percent": "6"
        },
        {
            "name": "Bacterial infections",
            "percent": "3-4"
        },
        {
            "name": "Arrhythmia",
            "percent": "5"
        },
        {
            "name": "Aphasia",
            "percent": "3-4"
        },
        {
            "name": "Delirium",
            "percent": "4"
        },
        {
            "name": "Hypertension",
            "percent": "3"
        },
        {
            "name": "Renal insufficiency",
            "percent": "3"
        },
        {
            "name": "grades",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "grades",
            "percent": "2"
        },
        {
            "name": "Viral infections",
            "percent": "2"
        },
        {
            "name": "Fatigue",
            "percent": "2"
        },
        {
            "name": "Dehydration",
            "percent": "2"
        },
        {
            "name": "Dyspnea",
            "percent": "2"
        },
        {
            "name": "Tachycardia",
            "percent": "1"
        },
        {
            "name": "Decreased appetite",
            "percent": "1"
        },
        {
            "name": "Pain in extremity",
            "percent": "1"
        },
        {
            "name": "Tremor",
            "percent": "1"
        },
        {
            "name": "Pleural effusion",
            "percent": "1"
        },
        {
            "name": "Vomiting",
            "percent": "1"
        },
        {
            "name": "Abdominal pain",
            "percent": "1"
        },
        {
            "name": "Edema",
            "percent": "1"
        },
        {
            "name": "Motor dysfunction",
            "percent": "1"
        },
        {
            "name": "Back pain",
            "percent": null
        },
        {
            "name": "Muscle pain",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Thrombosis",
            "percent": null
        }
    ]
}